AU2010267835C1 - Diagnosis and treatment of Alzheimer's disease - Google Patents

Diagnosis and treatment of Alzheimer's disease Download PDF

Info

Publication number
AU2010267835C1
AU2010267835C1 AU2010267835A AU2010267835A AU2010267835C1 AU 2010267835 C1 AU2010267835 C1 AU 2010267835C1 AU 2010267835 A AU2010267835 A AU 2010267835A AU 2010267835 A AU2010267835 A AU 2010267835A AU 2010267835 C1 AU2010267835 C1 AU 2010267835C1
Authority
AU
Australia
Prior art keywords
snp
gene
snps
disease
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010267835A
Other languages
English (en)
Other versions
AU2010267835B2 (en
AU2010267835A1 (en
Inventor
Michael John Owen
Julie Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College Cardiff Consultants Ltd
Original Assignee
University College Cardiff Consultants Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0911539A external-priority patent/GB0911539D0/en
Priority claimed from GB0913357A external-priority patent/GB0913357D0/en
Priority claimed from GB0917326A external-priority patent/GB0917326D0/en
Application filed by University College Cardiff Consultants Ltd filed Critical University College Cardiff Consultants Ltd
Publication of AU2010267835A1 publication Critical patent/AU2010267835A1/en
Publication of AU2010267835B2 publication Critical patent/AU2010267835B2/en
Priority to AU2014265063A priority Critical patent/AU2014265063B2/en
Application granted granted Critical
Publication of AU2010267835C1 publication Critical patent/AU2010267835C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2010267835A 2009-07-03 2010-06-22 Diagnosis and treatment of Alzheimer's disease Ceased AU2010267835C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2014265063A AU2014265063B2 (en) 2009-07-03 2014-11-20 Diagnosis and treatment of Alzheimer's disease

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0911539A GB0911539D0 (en) 2009-07-03 2009-07-03 Diagnosis of alzheimer's disease
GB0911539.5 2009-07-03
GB0913357.0 2009-07-31
GB0913357A GB0913357D0 (en) 2009-07-31 2009-07-31 Diagnosis of alzheimer's disease
GB0917326.1 2009-10-03
GB0917326A GB0917326D0 (en) 2009-10-03 2009-10-03 Diagnosis of alzheimer's disease
PCT/GB2010/001208 WO2011001135A2 (en) 2009-07-03 2010-06-22 Diagnosis and treatment of alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014265063A Division AU2014265063B2 (en) 2009-07-03 2014-11-20 Diagnosis and treatment of Alzheimer's disease

Publications (3)

Publication Number Publication Date
AU2010267835A1 AU2010267835A1 (en) 2011-12-15
AU2010267835B2 AU2010267835B2 (en) 2014-11-06
AU2010267835C1 true AU2010267835C1 (en) 2015-02-26

Family

ID=43014386

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010267835A Ceased AU2010267835C1 (en) 2009-07-03 2010-06-22 Diagnosis and treatment of Alzheimer's disease

Country Status (8)

Country Link
US (3) US20120122703A1 (https=)
EP (2) EP2891723B1 (https=)
JP (2) JP5917395B2 (https=)
CN (2) CN102471800A (https=)
AU (1) AU2010267835C1 (https=)
CA (1) CA2766876C (https=)
NZ (1) NZ596614A (https=)
WO (1) WO2011001135A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2766876C (en) * 2009-07-03 2020-01-28 University College Cardiff Consultants Limited Variants of clu/apoj, picalm, abca7, cr1 and bin1 gene loci and the ms4a gene cluster for the diagnosis of alzheimer's disease
WO2011024035A1 (en) * 2009-08-27 2011-03-03 Institut Pasteur De Lille Method for determining the risk of occurrence of alzheimer's disease
GB201212334D0 (en) * 2012-07-11 2012-08-22 Warwick The Therapeutic targets for alzheimers disease
CN104102839B (zh) * 2013-11-16 2017-10-27 西安电子科技大学 一种基于多尺度网格曲面形状特征的阿尔茨海默病脑皮层自动分类方法
CN105969885A (zh) * 2016-06-24 2016-09-28 江苏雄鸣医药科技有限公司 一种阿尔兹海默症的基因诊断试剂盒
CN106978475A (zh) * 2016-08-17 2017-07-25 上海易瑞生物科技有限公司 一种阿尔茨海默氏病易感基因检测分型试剂盒及其应用
CN106290823A (zh) * 2016-10-18 2017-01-04 上海凯璟生物科技有限公司 一种阿尔兹海默综合症标志物abca7检测试剂盒和制备方法
US11725232B2 (en) * 2016-10-31 2023-08-15 The Hong Kong University Of Science And Technology Compositions, methods and kits for detection of genetic variants for alzheimer's disease
US20210293794A1 (en) * 2017-02-24 2021-09-23 University Of Hawii Cancer Center Metabolic biomarkers for the identification and characterization of alzheimers disease
KR101933847B1 (ko) 2017-05-15 2018-12-28 조선대학교산학협력단 알츠하이머병 위험도와 관련된 apoe 프로모터 단일염기변이 및 이것의 용도
WO2018212371A1 (ko) * 2017-05-17 2018-11-22 조선대학교산학협력단 알츠하이머병 위험도와 관련된 apoe 프로모터 단일염기변이 및 이것의 용도
JP7399465B2 (ja) * 2017-05-15 2023-12-18 インフォメディテック・カンパニー，リミテッド アルツハイマー病の危険性と関連するａｐｏｅプロモーターの一塩基多型およびその使用
WO2019178167A1 (en) * 2018-03-13 2019-09-19 I2Dx, Inc. Electronic delivery of information in personalized medicine
EP3794345B1 (en) * 2018-05-18 2025-02-26 Anavex Life Sciences Corp. Optimized sigma-1 agonist method of responder selection and treatment
CN110607364B (zh) * 2019-11-01 2023-04-28 北京中医药大学 通过检测snp位点确定等位基因的基因型的方法
KR102561438B1 (ko) * 2020-11-04 2023-07-28 사회복지법인 삼성생명공익재단 뇌 아밀로이드 베타 축적 가능성을 예측하는 방법
JP7731540B2 (ja) * 2021-03-26 2025-09-01 国立研究開発法人農業・食品産業技術総合研究機構 アミロイドβ蓄積リスクの有無の指標とする方法、一塩基多型（ＳＮＰ）の存在又は非存在を検出する方法、組成物、及びキット
US20240203524A1 (en) * 2021-04-13 2024-06-20 Kyoto University Information processing method, information processing device, and storage medium
CL2021001380A1 (es) 2021-05-26 2022-01-14 Corporacion Centro Int De Biomedicina Icc Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias.
KR102775636B1 (ko) * 2022-03-15 2025-03-05 사회복지법인 삼성생명공익재단 유럽 인구 데이터 기반 알츠하이머병 치매의 발병 위험군 또는 조기 증상 발현 위험군, 기억상실형 경도인지장애의 발병 위험군 및/또는 아밀로이드β 침착에 대한 PET 양성 위험군을 예측하기 위한 정보를 제공하는 방법
CN114736963B (zh) * 2022-05-25 2023-03-24 首都医科大学宣武医院 一种用于预测阿尔茨海默病发病风险的物质的组合、试剂盒及应用
US12518859B2 (en) * 2023-07-26 2026-01-06 Helix, Inc. Systems and methods for providing test results of gene sequencing data on a recurring basis
KR102940935B1 (ko) * 2024-02-15 2026-03-17 이화여자대학교 산학협력단 고인지예비능 생체표지자로서의 snp 및 이의 이용

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2765591B1 (fr) * 1997-07-01 2002-08-09 Pasteur Institut Procede de diagnostic de la maladie d'alzheimer
WO2006138716A2 (en) * 2005-06-17 2006-12-28 Brt Laboratories, Inc. Thermodynamically defined gene specific primers
JP2007166962A (ja) * 2005-12-21 2007-07-05 Japan Health Science Foundation アルツハイマー病の予測または診断の方法
EP2082343A2 (en) * 2006-11-02 2009-07-29 Genizon Biosciences Inc. Genemap of the human genes associated with asthma disease
SG177960A1 (en) * 2007-04-17 2012-02-28 Santen Pharmaceutical Co Ltd Method for determination of onset risk of glaucoma
CA2766876C (en) * 2009-07-03 2020-01-28 University College Cardiff Consultants Limited Variants of clu/apoj, picalm, abca7, cr1 and bin1 gene loci and the ms4a gene cluster for the diagnosis of alzheimer's disease

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Burdon KP et al. Genetic analysis of the clusterin gene in pseudoexfoliation syndrome. Mol Vis. 2008; 14: 1727-1736. Published online 2008 September 22 *
DATABASE refSNP [Online] NCBI refSNP Accession No. rs11136000 27 February 2004 (2004-02-27) *
NCBI Accession: NW_002885440 (Creation Date: 22 June 2009) *
NCBI Accession: Pr031544961 Date Manufactured: 21 December 2006 Retrieved from the Internet *
NCBI refSNP Accession rs3851179 Creation Date: 8 October 2002 *
NCBI refSNP Accession rs561655 Creation Date: 11 August 2000 *
NCBI refSNP Accession rs592297 Creation Date: 11 August 2000 *
Rafii MS et al. Recent developments in Alzheimer's disease therapeutics. BMC Med. 2009 Feb 19;7:7. Review. *

Also Published As

Publication number Publication date
EP2891723A1 (en) 2015-07-08
US20130288906A1 (en) 2013-10-31
NZ596614A (en) 2012-11-30
JP2014012007A (ja) 2014-01-23
HK1169455A1 (en) 2013-01-25
EP2891723B1 (en) 2017-10-04
JP2012531195A (ja) 2012-12-10
AU2010267835B2 (en) 2014-11-06
JP5917395B2 (ja) 2016-05-11
US20120122703A1 (en) 2012-05-17
CA2766876A1 (en) 2011-01-06
EP2449134B1 (en) 2016-07-27
US20150119264A1 (en) 2015-04-30
CN103409511A (zh) 2013-11-27
EP2449134A2 (en) 2012-05-09
WO2011001135A3 (en) 2011-06-30
JP5917460B2 (ja) 2016-05-18
CA2766876C (en) 2020-01-28
WO2011001135A9 (en) 2011-02-24
CN102471800A (zh) 2012-05-23
WO2011001135A2 (en) 2011-01-06
AU2010267835A1 (en) 2011-12-15

Similar Documents

Publication Publication Date Title
AU2010267835C1 (en) Diagnosis and treatment of Alzheimer's disease
Harold et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease
CA2275504C (en) Pharmacogenetic methods for use in the treatment of nervous system diseases
US20080152589A1 (en) Diagnostics and Therapeutics of Neurological Disease
US20240026454A1 (en) Single nucleotide polymorphism marker for predicting risk of alzheimers disease and use thereof
CA2721503A1 (en) Polymorphisms associated with age-related macular degeneration and methods for evaluating patient risk
WO2005017143A1 (en) Diagnosis and treatment of neurodegenerative disorders, involving the microtubule associated protein tau (mapt) gene
US20150044239A1 (en) Compositions and Methods for Diagnosing, Preventing and Treating Intracranial Aneurysms
US8137916B2 (en) Susceptibility gene for alzheimer's disease
US8377640B2 (en) Diagnostic screens for Alzheimer's disease
AU2014265063B2 (en) Diagnosis and treatment of Alzheimer's disease
US9127316B2 (en) Markers associated with Alzheimer'S disease
HK1169455B (en) Diagnosis and treatment of alzheimer's disease
EP2603606B1 (en) Methods and kits for of identifying a premature infant at risk of having or developing bronchopulmonary dysplasia
Jin Identification of functional variants in Alzheimer's disease-associated genes
Panitch Understanding the mechanisms and pathways of Alzheimer’s disease in APOE genotype sub-populations
US20120289593A1 (en) Methods for risk assessment, treating, and diagnosing myocardial infarction
JP2022150707A (ja) アミロイドβ蓄積リスクの有無の指標とする方法、一塩基多型（ＳＮＰ）の存在又は非存在を検出する方法、組成物、及びキット
Genet Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes
Eckart Identification and Functional Characterization of Genetic Risk Factors in Alzheimer´ s Disease

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 14 NOV 2014 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 14 NOV

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired